[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659478":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":25,"studyPopulation":29,"armGroups":25,"interventions":25,"overallOfficials":25,"centralContacts":25,"locations":30,"responsibleParty":49,"collaborators":25,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":25,"maxAge":25,"enrollmentInfo":59,"targetDuration":25,"studyType":62,"phases":25,"briefSummary":63,"conditions":64,"keywords":25,"overallStatus":33,"whyStopped":25,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de la Réunion","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":25},[9],{"measure":10,"description":11,"timeFrame":12},"Distribution of sociodemographic characteristics at diagnosis","Distribution of age at diagnosis (years), sex (male\u002Ffemale), ethnicity, and socioeconomic indicators among patients diagnosed with diffuse glioma in Réunion Island","two years",[14,18,22],{"measure":15,"description":16,"timeFrame":17},"Clinical presentation of diffuse gliomas at diagnosis","Clinical characteristics at diagnosis including presenting symptoms, performance status (e.g., Karnofsky Performance Status score), tumor location, and initial treatment modalities","2 years",{"measure":19,"description":20,"timeFrame":21},"Molecular characteristics of diffuse gliomas","Tumor molecular markers including IDH mutation status, 1p\u002F19q codeletion status, and MGMT promoter methylation status assessed at diagnosis","inclusion",{"measure":23,"description":24,"timeFrame":21},"Histopathological classification of diffuse gliomas","Histopathological classification of tumors according to the WHO classification of central nervous system tumors at diagnosis",null,{"allocation":25,"interventionModel":25,"interventionModelDescription":25,"primaryPurpose":25,"observationalModel":27,"timePerspective":28,"maskingInfo":25},"COHORT","CROSS_SECTIONAL","person with glioma at La Réunion Island",[31],{"facility":32,"status":33,"city":34,"state":25,"zip":35,"country":36,"countryCode":25,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Mélanie BEGORRE","RECRUITING","Saint-Pierre","97410","Reunion",{"type":38,"coordinates":39},"Point",[40,41],55.47811,-21.3393,{"lat":41,"lon":40},[44],{"name":45,"role":46,"phone":47,"phoneExt":25,"email":48},"CHU La Réunion DRCI","CONTACT","0262359000","promotion.drci@chu-reunion.fr",{"type":50,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100659478","diffuse-gliomas-in-reunion-island-establishment-of-an-epidemiological-clinical-biological-and-socio-anthropological-cohorte-100659478",false,"NCT07865195","Diffuse Gliomas in Reunion Island: Establishment of an Epidemiological, Clinical-biological and Socio-anthropological Cohorte","GLIORUN","Inclusion Criteria:\n\nQuantitative study (retrospective and prospective components):\n\nPatients aged 18 and over:\n\n* With a histological diagnosis of incident diffuse glioma since January 1, 2018\n* Residing in Réunion at the time of diagnosis,\n* Having been informed about the study procedures\n* Having agreed to participate in the study\n\nSocio-anthropological study (prospective component):\n\nPatients:\n\n* Meeting the inclusion criteria for the prospective quantitative study and agreeing to participate in the qualitative component,\n* Speaking French. • Able to participate in a face-to-face interview\n\nHealthcare Professional:\n\n* Professionals involved in the care of patients with brain tumors (medical, paramedical, social care, support care, etc.) who have agreed to participate in the study\n* The healthcare professionals concerned will be general practitioners, neurosurgeons, neurologists, radiation oncologists, medical oncologists, home healthcare physicians, palliative care physicians, pathologists, nurses responsible for diagnosis and follow-up, psychologists, social workers, and dietitians.\n\nExclusion Criteria:\n\nRegarding the quantitative study:\n\nPatient:\n\nRefusing to participate in the quantitative study Having a recurrent diffuse glioma Person deprived of their liberty and judgment by judicial or administrative decision, and person subject to a legal protection measure: guardianship or curatorship, under judicial protection, under legal guardianship, etc.)\n\nRegarding the socio-anthropological study:\n\nPatient:\n\nRefusing to participate in the qualitative study Does not speak French Having serious somatic or mental health problems incompatible with the interview Healthcare professionals: Refusing to participate in the study","ALL",{"count":60,"type":61},214,"ESTIMATED","OBSERVATIONAL","To date, very little data exists on gliomas in the Réunion population, in terms of epidemiology, socio-cultural aspects, clinical or biological factors, and care pathways. However, the Réunion population is multicultural and highly cosmopolitan, experiencing rapid aging, and its socio-economic indicators are among the most pessimistic of all French departments. Furthermore, the healthcare services available on the island are less comprehensive than those in metropolitan France (Insee 2018). Finally, the management of patients with gliomas, particularly high-grade gliomas, remains very complex, with significant medical and social challenges (supportive care, end-of-life care, etc.). Healthcare professionals agree that these specialized facilities are insufficient to meet the care needs in Réunion (post-acute care, palliative care units, supportive care, etc.).\n\nGlioRun is a retrospective and prospective mixed-methods cohort study, combining epidemiological and socio-anthropological approaches, which aims to produce data to improve care and the experiences of patients and their relatives on Reunion Island, and reduce the number of medical evacuations to mainland France.",[65],"Glioblastoma","2026-10-05",{"date":68,"type":69},"2026-10-08","ACTUAL",{"date":71,"type":69},"2025-04-07",{"date":73,"type":61},"2028-11-07",{"name":5,"class":6},1]